Latest 5 articles from heartwire
- FDA panel recommends new studies of ASD occluders
May 26, 2012 11:30 EDT - Adhering to CPAP for OSA could thwart new hypertension
May 25, 2012 11:00 EDT - Dabigatran fatal bleeding less than in clinical trials: New EMA data
May 25, 2012 10:30 EDT - Hope rekindled for ACE inhibitors, ARBs in preserved-EF heart failure
May 24, 2012 14:30 EDT - Missing data lead FDA panel to vote against rivaroxaban for ACS
May 23, 2012 17:19 EDT
ISAR-REACT 4 on bivalirudin; IC vs IV abciximab in AIDA STEMI; vorapaxar in TRACER; ADOPT: apixaban vs enoxaparin; rivaroxaban in ATLAS ACS 2
Posted Nov 13, 2011
at 11:25 PM, EDT
by Steven Rourke
Watch results, analysis, and clinical implications of today’s late-breaking clinical trials from the American Heart Association 2011 Scientific Sessions.
See:
- ISAR-REACT 4: Bivalirudin preferable to abciximab/heparin in NSTEMI
- AIDA STEMI: No benefit of IC over IV abciximab
- TRACER: Novel thrombin blocker vorapaxar stumbles in ACS, ups bleeding risk
- ADOPT: Extended apixaban no better than standard enoxaparin for VTE in medically ill
- ATLAS ACS 2: Low-dose rivaroxaban looks good in ACS
Previous posts
FAME or COURAGE: Can we have both?
1 Comments |
Posted May 19, 2012
at 07:50 AM, EDT by Melissa
at 07:50 AM, EDT by Melissa
"Consent the stent" campaign--long overdue!
No comments |
Posted May 09, 2012
at 10:05 PM, EDT by Melissa
at 10:05 PM, EDT by Melissa
Hospital interest rates: Taking the family farm
10 Comments |
Posted Apr 24, 2012
at 08:22 PM, EDT by Melissa
at 08:22 PM, EDT by Melissa
Dr Dean Ornish with manna for the masses
16 Comments |
Posted Mar 28, 2012
at 10:05 AM, EDT by Melissa
at 10:05 AM, EDT by Melissa
Physicians remember: Mainstream-medicine haters are people too
24 Comments |
Posted Mar 27, 2012
at 12:37 PM, EDT by Melissa
at 12:37 PM, EDT by Melissa
Also from theheart.org















Comments